^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Mucosal Melanoma

    Related cancers:
    23h
    Sinonasal mucosal melanoma of the maxillary sinus: Diagnostic challenges and therapeutic insights from a case report. (PubMed, Radiol Case Rep)
    Adjuvant intensity-modulated radiotherapy was subsequently delivered. This case highlights the pivotal role of multimodality imaging in characterizing sinonasal tumors, guiding staging and therapeutic decision-making, and emphasizes the importance of maintaining a high index of suspicion when encountering atypical or persistent maxillary sinus lesions.
    Journal
    |
    MLANA (Melan-A)
    3d
    Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Fudan University
    New P2 trial
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation
    |
    Avastin (bevacizumab) • carboplatin • albumin-bound paclitaxel • iparomlimab (QL1604)
    5d
    Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort. (PubMed, JCO Precis Oncol)
    HRD defines a biologically distinct subset of skin cancers and is not predictive of ICI response or improved outcomes. The high prevalence of HRD in acral and mucosal melanoma highlights the need to investigate HRD-directed therapies strategies in this distinct cohort, such as poly (ADP-ribose) polymerase inhibitors or platinum-based therapies.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    MSI-H/dMMR • HRD
    7d
    Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    carboplatin • paclitaxel • AiRuiLi (adebrelimab)
    8d
    Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma (clinicaltrials.gov)
    P3, N=632, Recruiting, mAbxience Research S.L. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab)
    12d
    Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial primary completion date • First-in-human
    |
    BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • TIDAL-01
    12d
    Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov)
    P1, N=12, Terminated, Mayo Clinic | Trial completion date: Jan 2027 --> Sep 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Sep 2025; Lack of funding; lack of objective response
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    VSV-IFNbetaTYRP1
    15d
    Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov)
    P2, N=105, Recruiting, NYU Langone Health | N=69 --> 105 | Trial completion date: Dec 2025 --> Feb 2028 | Trial primary completion date: Jun 2025 --> Aug 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Opdualag (nivolumab/relatlimab-rmbw) • Kevzara (sarilumab)
    16d
    Surgical treatment of vaginal and vulvar melanoma: a 18-year retrospective study. (PubMed, Eur J Surg Oncol)
    Vaginal and vulvar melanoma have a poor prognosis. Extensive surgery with anterior or posterior pelvectomy shoud only be performed to obtained free margin with caution in well selected patient. Radiological lymph node should contraindicate primary surgical strategy. Neodjuvant immunotherapy could help to obtained free margin in patient with high risk of invaded margin, these patients should be included in randomized controlled clinical trials.
    Clinical • Retrospective data • Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    BRAF mutation • KIT mutation
    20d
    PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study (clinicaltrials.gov)
    P=N/A, N=10, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    29d
    R3767-ONC-2011: Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov)
    P3, N=1546, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)